

# Advances in Biomaterial Design and Application for Glaucoma Therapy

Jui-Yang Lai, Ph.D.

Department of Biomedical Engineering,  
Chang Gung University, TAIWAN




**CRS** 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**


*THE FUTURE OF DELIVERY SCIENCE*

# Functional Biomaterial Lab




## Research Interest

- Ophthalmic Biomaterials
- Drug Delivery
- Nanomedicine
- Tissue Engineering





# Eye



<http://www.nei.nih.gov/health/eyediagram/eyeimages4.asp>

**2<sup>nd</sup> global leading cause of blindness**



**World Health Organization**

[http://www.who.int/Blindness/Vision2020\\_report.pdf](http://www.who.int/Blindness/Vision2020_report.pdf)

**Glaucomatous Case Number ↑**

CONTROLLED RELEASE SOCIETY



**CRS 2023 ANNUAL MEETING & EXPOSITION**

JULY 24-28, 2023 **Paris Hotel » Las Vegas, NV, USA**


**THE FUTURE OF DELIVERY SCIENCE**

# Glaucoma: Feature

- Elevated eye pressure (> 21 mmHg)



## Retinal ganglion cell apoptosis



[https://edc2.healthtap.com/ht-staging/user\\_answer/avatars/1106716/large/open-uri20130505](https://edc2.healthtap.com/ht-staging/user_answer/avatars/1106716/large/open-uri20130505)


CONTROLLED RELEASE SOCIETY

**CRS** 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**


THE FUTURE OF DELIVERY SCIENCE

# Glaucoma: Outcome




## Optic nerve depression

a



b



<https://www.cceye.com.tw/eyecare/view/446>

CONTROLLED RELEASE SOCIETY


# CRS 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023


Paris Hotel » Las Vegas, NV, USA

THE FUTURE OF DELIVERY SCIENCE

# Ophthalmic Drug Formulations



## Functional biomaterial carrier as DDS



Short, Toxicol. Pathol. 2008;36:49-62

- **Injectable Thermogel**
- **Nanoceria Eye Drop**
  - Improve bioavailability
  - Completely alleviate symptoms


CONTROLLED RELEASE SOCIETY

**CRS** 2023 ANNUAL MEETING & EXPOSITION


JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE


# ***Biodegradable In Situ Forming DDS***



## **Intracameral drug delivery**






**Biomaterials** 2012;33:2372-2387




# Synthesis of gelatin-g-PNIPAAm

# Intraocular Pressure & Pupil Diameter




- GN-Drug: significant decreases in IOP & pupil diameter were noted over 2 weeks, suggesting intense pharmacological activity and high ocular drug bioavailability

# Next Stage



- Our findings support the hypothesis that the combination of **degradable** with **temperature-sensitive** features of carriers increases drug delivery performance



**Extended Release**

**Functional Boost**




CONTROLLED RELEASE SOCIETY  
**CRS** 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**


*THE FUTURE OF DELIVERY SCIENCE*

# Extended Release

## Chain Length of Monothiol-Terminated Alkyl Carboxylic Acid






### Carbon number of PN segment



Acta Biomater. 2017;49:344-357

### In vivo release profile



CONTROLLED RELEASE SOCIETY

**CRS** 2023 ANNUAL MEETING & EXPOSITION



JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE

# Functional Boost



## Cytoprotective Antiglaucoma

### DDS





### GA Grafting

### Effect



Biomacromolecules 2015;16:2950–2963

## Improved Antioxidant






CONTROLLED RELEASE SOCIETY

**CRS 2023 ANNUAL MEETING & EXPOSITION**  
JULY 24-28, 2023 **Paris Hotel » Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE



# Glaucomatous Optic Neuropathy





- The optic disc is composed of neural, vascular, and connective tissues
- Glaucomatous optic neuropathy involves damage and remodeling of the optic disc tissues and lamina cribrosa that lead to vision loss

CONTROLLED RELEASE SOCIETY

**CRS** 2023 ANNUAL MEETING & EXPOSITION  
JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE

# Prooxidant/Antioxidant Balance



J. Control. Release 2020;317:246-258



CONTROLLED RELEASE SOCIETY

**CRS** 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**


THE FUTURE OF DELIVERY SCIENCE

# ***Characterization***




### 3,4,5-trihydroxybenzoic acid

(THB)




### 3,4-dihydroxy-5-methoxybenzoic acid

(MB)




### 4-hydroxy-3,5-dimethoxybenzoic acid

## (p-DMB)







### 3-hydroxy-4,5-dimethoxybenzoic acid

## (*m*-DMB)



### 3,4,5-trimethoxybenzoic acid








(TMB)



- Increasing the number of methylation of OH groups induces a **hypsochromic shift**
- An additional spectral peak was noted in the range of 7.0-7.5 (**2H, s, 2-H and 6-H**) ppm

# Cellular Response

THB has strong antioxidant activity but also could act as pro-oxidant




CONTROLLED RELEASE SOCIETY

**CRS 2023 ANNUAL MEETING & EXPOSITION**



JULY 24-28, 2023 **Paris Hotel » Las Vegas, NV, USA**

**THE FUTURE OF DELIVERY SCIENCE**

# In Vivo Study



HDA  
C3




CONTROLLED RELEASE SOCIETY

**CRS** 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**





THE FUTURE OF DELIVERY SCIENCE

# In Vivo Study




# Nanocapsular System

## Polyester-Based Hollow Nanocarrier



Nanoscale 2017;9:11754-11764





CONTROLLED RELEASE SOCIETY

# CRS 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**


THE FUTURE OF DELIVERY SCIENCE

# Eye Drop




Glaucoma model

Treatment



Biomaterials 2020;243:119961









CONTROLLED RELEASE SOCIETY

**CRS** 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE

# Characterization




CONTROLLED RELEASE SOCIETY

**CRS** 2023 ANNUAL MEETING & EXPOSITION



JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE


# Functional Assay




## Anti-Oxidant





## Anti-Inflammator



## TJ Opening



## Cell Targeting










CONTROLLED RELEASE SOCIETY

**CRS** 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE

# In Vivo Study






CONTROLLED RELEASE SOCIETY

**CRS2023 ANNUAL MEETING & EXPOSITION**  
JULY 24-28, 2023 **Paris Hotel » Las Vegas, NV, USA**

**THE FUTURE OF DELIVERY SCIENCE**

# Effect of Shell Thickness



Theranostics 2021;11:5447-5463


CONTROLLED RELEASE SOCIETY

**CRS** 2023 ANNUAL MEETING & EXPOSITION





JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE

# Effect of Chitosan DD



## Amination-Mediated Drug Delivery Performance for Acute Glaucoma Therapy



Chem. Eng. J. 2023;451:138620



CONTROLLED RELEASE SOCIETY


**CRS** 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE

## Concluding Remarks

- Our findings suggest that multifunctional biomaterials may have potential for application as **injectable depot** or **eye drop formulation** for intraocular drug delivery
- Structure-property-function relationship can be tailored to the needs of **therapeutic DDS** for treating ocular diseases




### Acknowledgments

*Group member: graduate students*  
*Financial support: NSTC & NHRI*

# Disease Treatment: DDS/ITNP


The development of efficient therapies for ocular diseases remains a significant challenge because of the static and dynamic barriers in the eye. A variety of pharmaceutical strategies have been explored to overcome these ocular physiological barriers and thereby improve therapeutic bioavailability in both anterior and posterior ocular tissues. This mini-review summarizes, analyzes, and discusses recent advances in the field of ophthalmic drug delivery systems (DDSs). Specifically, the focus is on design strategies using stimuli-responsive polymers and their applications for the treatment of prevalent ocular diseases such as dry eye, ocular infection, glaucoma, and age-related macular degeneration. The stimuli-responsive polymers are categorized according to their responses in various ocular environmental conditions (such as temperature, pH, and ions). Additionally, general strategies and methodologies for the construction of effective ophthalmic stimuli-responsive DDSs are investigated by exploiting key parameters such as the stimuli-response type, ocular biocompatibility, ocular biodegradability, drug encapsulation and release, as well as the modifiable structure of the polymers. Also discussed in this review are the interrelationships among the designed structures, properties, and functions of the stimuli-responsive DDSs and their pharmacological treatment efficacies. In summary, we believe that the recent progress in the field of stimuli-responsive DDSs constitutes a significant advance for the development of effective pharmacological treatments for eye disorders.

## [Polymer Chemistry Pioneering Investigators Issue]



Intrinsically therapeutic nanoparticles (ITNPs) are a special class of nanomaterials with capabilities of self-triggering bioactive activities (without drug) when interacting with biological entities of interest. Typical bioactive features of ITNPs are antioxidant, antiinflammatory, antiangiogenic, and antibacterial properties, which can be medicinally exploited to treat a variety of diseases. Recently, ITNPs have considerably contributed to the development of numerous therapeutic modalities, simplified the formulation of nanotherapeutics, and promoted the translations of these intriguing biomaterials from bench to bedside. Therefore, this review summarizes, analyzes, and discusses recent advances of ITNPs in the treatment of diseases associated with four main risk factors: oxidative stress, inflammation, angiogenesis, and infection. Specifically, an update on the syntheses, bioactive properties, and biomedical assessments of ITNPs is provided. Moreover, therapeutic efficacies of ITNPs in pre/clinical trials are deliberated with respect to their physical/chemical characteristics; challenges and perspectives toward the clinical translation of ITNPs are also highlighted.

[WOS Highly Cited Paper]





CONTROLLED RELEASE SOCIETY

# CRS 2023 ANNUAL MEETING & EXPOSITION

JULY 24-28, 2023 **Paris Hotel » Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE

# Macular Degeneration: Nanotherapeutics



ACS Nano 2023;17:168-183




JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**

ACS Nano 2023

THE FUTURE OF DELIVERY SCIENCE

# Corneal Alkali Burn: Nanomedicine



Adv. Sci. 2023;10:e2302174